Silence Therapeutics plc (SLN) stock: key figures, P/E, revenue and dividend
Health Care · ISIN US82686Q1013
Silence Therapeutics plc financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 559,000.00 USD |
| Gross profit | 344,000.00 USD |
| Operating income | -91.08 m USD |
| EBIT | -88.60 m USD |
| Net income | -88.61 m USD |
| Diluted EPS – continuing operations | -0.63 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
More stocks
- Qingdao Hanhe Cable Co Ltd (002498.SZ)
- Fibocom Wireless Inc (300638.SZ)
- Shanxi Taigang Stainless Steel Co Ltd (000825.SZ)
- Zhuhai CosMX Battery Co Ltd (688772.SS)
- IGO Ltd (IGO.AX)
- NBT BANCORP INC (NBTB)
- Walvax BioTech (300142.SZ)
- Shanghai Originaldow Advanced (603991.SS)
- Marketech International Corp (6196.TW)
- Mr Price Group Ltd (MRP.JO)
- Guangdong Create Century Intelligent Equipment Group Corp Ltd (300083.SZ)
- Premium Brands Holdings Corporation (PBH.TO)
Not investment advice. All data without warranty, price as of 02.11.2026. Details in the risk notice.